APA (7th ed.) Citation

Subbiah, V., Solit, D., Chan, T., & Kurzrock, R. (2020). The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: A decision centered on empowering patients and their physicians. Annals of Oncology, 31(9), 1115. https://doi.org/10.1016/j.annonc.2020.07.002

Chicago Style (17th ed.) Citation

Subbiah, V., D.B Solit, T.A Chan, and R. Kurzrock. "The FDA Approval of Pembrolizumab for Adult and Pediatric Patients with Tumor Mutational Burden (TMB) ≥10: A Decision Centered on Empowering Patients and Their Physicians." Annals of Oncology 31, no. 9 (2020): 1115. https://doi.org/10.1016/j.annonc.2020.07.002.

MLA (9th ed.) Citation

Subbiah, V., et al. "The FDA Approval of Pembrolizumab for Adult and Pediatric Patients with Tumor Mutational Burden (TMB) ≥10: A Decision Centered on Empowering Patients and Their Physicians." Annals of Oncology, vol. 31, no. 9, 2020, p. 1115, https://doi.org/10.1016/j.annonc.2020.07.002.